US 2025/0223554 A1 · METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY

Abstract

Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.

Claims25

Dependent claims

A method of producing gene-modified dendritic cells for cancer therapy comprising:

(a) obtaining CD34+ hematopoietic stem cells (HSCs);
(b) expanding the CD34+ HSCs;
(c) introducing one or more exogenous genes into the HSCs to produce gene-modified HSCs by infection with a viral vector comprising the genes;
(d) differentiating the gene-modified HSCs into monocytes;
(e) maturing the monocytes into immature dendritic cells (DCs);
(f) maturing the immature Dcs into mature dendritic cells (MaDCs) to produce gene-modified (recombinant) MaDCs;
and
(g) harvesting the gene-modified MaDCs from the culture.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/008,154Filed 2 Jan 2025

Priority

5 Jan 2024

Published

10 Jul 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12N 5/0639
Cells from the blood or the immune system: dendritic cells, e.g. Langherhans cells in the epidermis
A61K 35/14
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61P 35/00
Antineoplastic agents
C12N 5/562
Physical preservation processes for animal cells or human cells: temperature processes, e.g. following predefined temperature changes over time

Methods and compositions using recombinant dendritic cells for cancer therapy

Life of this patent

Methods and compositions using recombinant dendritic cells for cancer therapy

Life of this patent

Abstract

Claims25